Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Change in Accured Expenses (2023 - 2025)

Tonix Pharmaceuticals Holding (TNXP) has 3 years of Change in Accured Expenses data on record, last reported at $1.2 million in Q3 2025.

  • For Q3 2025, Change in Accured Expenses rose 163.16% year-over-year to $1.2 million; the TTM value through Sep 2025 reached $3.2 million, down 21.07%, while the annual FY2024 figure was $1.2 million, 33.37% down from the prior year.
  • Change in Accured Expenses reached $1.2 million in Q3 2025 per TNXP's latest filing, down from $3.4 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $4.4 million in Q4 2023 and bottomed at -$3.0 million in Q1 2023.
  • Average Change in Accured Expenses over 3 years is $421727.3, with a median of $913000.0 recorded in 2024.
  • The widest YoY moves for Change in Accured Expenses: up 268.35% in 2025, down 68.96% in 2025.
  • A 3-year view of Change in Accured Expenses shows it stood at $4.4 million in 2023, then plummeted by 65.02% to $1.5 million in 2024, then decreased by 19.25% to $1.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were $1.2 million in Q3 2025, $3.4 million in Q2 2025, and -$2.9 million in Q1 2025.